Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease

• Status: Completed
• Trial end date: 2009-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The study is designed to measure the efficacy and safety of levetiracetam on levodopa-induced dyskinesias in late-stage Parkinson's disease. The patients are planned to be treated with levetiracetam (up to 2000 mg per day) or placebo for 13 weeks. Efficacy measure is the modified AIMS.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Technische Universität Dresden
• Collaborator: UCB Pharma GmbH
• Treatments: Etiracetam; Levetiracetam; Levodopa; Piracetam

Criteria

Inclusion Criteria:

• Advanced Parkinson's disease (Hoehn & Yahr II-IV)

• Age of 30 to 80 years

• Levodopa-induced dyskinesias of at least 25% of the waking day and with moderate disability

• Stable dosage of antiparkinson medication and/or stable deep brain stimulation parameters for at least 4 week prior inclusion

• Written informed consent

Exclusion Criteria:

• Atypical parkinsonian syndromes

• Treatment with antipsychotics

• Epilepsia or seizure in the history

• Deep brain stimulation other than DBS in STN

• Pregnant or lactating women

• Severe dementia